Strong survival data set stage for first-half Abraxane filings in pancreatic cancer
This article was originally published in Scrip
Executive Summary
Celgene will present further details of its Phase III MPACT trial with Abraxane later this week, showing that the nanoparticle albumin-bound formulation of paclitaxel added to gemcitabine significantly improved overall survival - and doubled two-year survival - over gemcitabine alone in the first-line treatment of advanced pancreatic cancer.